1. Introduction
1.1 Executive Summary
1.2 Market Definition
1.3 Scope of the Study
2. Research Methodology
2.1 Secondary Research
2.2 Primary Research
2.3 Analytic Tools and Model
2.4 Economic Indicator
2.4.1 Base Year, Base Currency, Forecasting Period
2.5 Expert Validation
2.6 Study Timeline
3. Market Analysis
3.1 Industry Value Chain Analysis
3.2 Porter's Five Analysis
3.2.1 Bargaining Power of Buyers
3.2.2 Bargaining Power of Suppliers
3.2.3 Threats of Substitutes
3.2.4 Threats of New Entrants
3.2.5 Industry Rivalry
3.3 PESTLE Analysis
3.3.1 Political
3.3.2 Economical
3.3.3 Social
3.3.4 Technological
3.3.5 Legal
3.3.6 Environmental
3.4 SWOT Analysis
3.4.1 Strengths
3.4.2 Weakness
3.4.3 Opportunities
3.4.4 Threats
3.5 Y-O-Y Analyses
4. Market Dynamics
4.1 Drivers
4.1.1 Strong encouragement from the governments
4.1.2 Complexities in alternative diabetic therapies
4.1.3 Rise in the number of diabetics
4.2 Restraints
4.2.1 Cost sensitivity issues
4.2.2 Lack of awareness among people
4.2.3 Regulatory framework issues
4.3 Opportunities
4.3.1 approvals of new drugs such as Canagliflozin and dapagliflozin
4.4 Challenges
4.4.1 Cost sensitivity
4.4.2 Low awareness
4.4.3 Regulatory Framework
4.4.4 Effective Disease Management
5. The Middle East & Africa Diabetes Drugs Market - By Drugs
5.1 Insulin Derivatives
5.1.1 Rapid-acting insulin
5.1.2 Intermediate-acting insulin
5.1.3 Long-acting insulin
5.2 Oral Diabetic Medication Drugs
5.2.1 Sulfonylurea
5.2.2 Metformin
5.2.3 Alpha-Glucosidase inhibitor
5.2.4 Thiazolidinediones
5.2.5 Biguanide
5.2.6 Meglitinides
5.2.7 GPP4-Inhibitors
6. The Middle East & Africa Diabetes Drugs Market - By Country
6.1.Introduction
6.2.The Middle East
6.3.Africa
6.4 Rest of Middle East & Africa
7. Company Profiles
7.1 Novo Nordisk
7.2 Sanofi
7.3 MSD
7.4 Eli Lilly
7.5 Medtronic
7.6 Novartis
7.7 AstraZeneca
7.8 Xinbai Pharmaceutical
7.9 Wanbang Biopharma
7.10 Halozyme Therapeutics
7.11 Oramed Pharmaceuticals Inc.
7.12 Merck KGaA
7.13 Dongbao Enterprise Group Co., Ltd.
7.14 Biocon
7.15 Boehringer Ingelheim
8. The Middle East & Africa Diabetes Drugs Market - Competitive Landscape
8.1 Market Share Analysis
8.2 Strategies Adopted by top companies
8.3 Mergers, Acquisitions, Collaborations & Agreements
9. Market Insights
9.1 Insights of Industry Experts
9.2 Investment Opportunities
9.3 Analyst Opinion
10. Appendix
10.1 List of Tables
10.2 List of Figures
